Wealthfront Advisers’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.37M | Buy |
34,789
+9,905
| +40% | +$1.94M | 0.01% | 370 |
|
|
2026
Q1 | $4.88M | Buy |
24,884
+1,584
| +7% | +$308K | 0.01% | 424 |
|
|
2025
Q4 | $4.04M | Sell |
23,300
-630
| -3% | -$115K | 0.01% | 444 |
|
|
2025
Q3 | $4.56M | Buy |
23,930
+480
| +2% | +$85.2K | 0.01% | 411 |
|
|
2025
Q2 | $4.21M | Buy |
23,450
+169
| +0.7% | +$29.4K | 0.01% | 417 |
|
|
2025
Q1 | $3.94M | Sell |
23,281
-199
| -0.8% | -$32.7K | 0.01% | 400 |
|
|
2024
Q4 | $3.54M | Sell |
23,480
-909
| -4% | -$141K | 0.01% | 399 |
|
|
2024
Q3 | $3.79M | Buy |
24,389
+2,420
| +11% | +$361K | 0.01% | 373 |
|
|
2024
Q2 | $3.01M | Buy |
21,969
+3,238
| +17% | +$443K | 0.01% | 384 |
|
|
2024
Q1 | $2.49M | Sell |
18,731
-1,379
| -7% | -$179K | 0.01% | 435 |
|
|
2023
Q4 | $2.77M | Buy |
20,110
+1,704
| +9% | +$224K | 0.01% | 384 |
|
|
2023
Q3 | $2.24M | Sell |
18,406
-700
| -4% | -$93.3K | 0.01% | 403 |
|
|
2023
Q2 | $2.69M | Sell |
19,106
-8,100
| -30% | -$1.12M | 0.01% | 355 |
|
|
2023
Q1 | $3.85M | Sell |
27,206
-730
| -3% | -$104K | 0.02% | 257 |
|
|
2022
Q4 | $4.37M | Buy |
27,936
+586
| +2% | +$84.2K | 0.02% | 227 |
|
|
2022
Q3 | $3.36M | Sell |
27,350
-19,791
| -42% | -$2.61M | 0.02% | 252 |
|
|
2022
Q2 | $6.27M | Buy |
47,141
+1,390
| +3% | +$189K | 0.03% | 152 |
|
|
2022
Q1 | $6.26M | Buy |
45,751
+29,338
| +179% | +$4.09M | 0.03% | 173 |
|
|
2021
Q4 | $2.84M | Buy |
16,413
+4,588
| +39% | +$698K | 0.01% | 315 |
|
|
2021
Q3 | $1.72M | Buy |
11,825
+5,470
| +86% | +$800K | 0.01% | 377 |
|
|
2021
Q2 | $839K | Buy |
6,355
+3,598
| +131% | +$471K | ﹤0.01% | 454 |
|
|
2021
Q1 | $354K | Buy |
2,757
+405
| +17% | +$49.9K | ﹤0.01% | 492 |
|
|
2020
Q4 | $280K | Buy |
2,352
+8
| +0.3% | +$975 | ﹤0.01% | 498 |
|
|
2020
Q3 | $268K | Sell |
2,344
-6
| -0.3% | -$709 | ﹤0.01% | 472 |
|
|
2020
Q2 | $268K | Sell |
2,350
-176
| -7% | -$18.7K | ﹤0.01% | 463 |
|
|
2020
Q1 | $203K | Sell |
2,526
-277
| -10% | -$28.7K | ﹤0.01% | 429 |
|
|
2019
Q4 | $299K | Sell |
2,803
-172
| -6% | -$17.9K | ﹤0.01% | 451 |
|
|
2019
Q3 | $318K | Buy |
2,975
+366
| +14% | +$37.6K | ﹤0.01% | 426 |
|
|
2019
Q2 | $266K | Buy |
2,609
+118
| +5% | +$11.3K | ﹤0.01% | 450 |
|
|
2019
Q1 | $224K | Sell |
2,491
-255
| -9% | -$22.1K | ﹤0.01% | 463 |
|
|
2018
Q4 | $229K | Buy |
+2,746
| New | +$257K | ﹤0.01% | 425 |
|
Other funds holding DGX
DSA
Wealthfront Advisers's DGX Position: Q2 2026 in Review
Wealthfront Advisers increased its Quest Diagnostics (DGX) stake by 40% in Q2 2026, buying an estimated $1.94M and bringing the position to 34,789 shares worth $7.37M. The position accounts for 0.01% of the portfolio, ranked #370.
Wealthfront Advisers first reported a position in DGX in Q4 2018 and has held it in 31 quarters since. 823 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Wealthfront Advisers held 34,789 shares of Quest Diagnostics worth $7.37M as of Q2 2026.
- Wealthfront Advisers bought 9,905 Quest Diagnostics shares in Q2 2026, an estimated $1.94M.
- Quest Diagnostics made up 0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #370 holding.
- Wealthfront Advisers first reported a position in Quest Diagnostics in Q4 2018 and has held it in 31 quarters since.
- 823 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.